Episkleritis

01Pathophysiology

The episclera is a thin, highly vascular connective tissue layer situated between the overlying conjunctiva and the underlying sclera. In episcleritis, inflammation is confined to this superficial episcleral layer, which is why the disease runs a benign and self-limiting course. The episcleral vascular plexus becomes engorged and inflamed, producing the characteristic redness.

Because the inflammation does not extend into the deeper scleral tissue, there is no structural threat to the globe. This is the single most important distinction from scleritis, where inflammation penetrates the full thickness of the scleral wall and can lead to thinning, perforation, and vision loss. The superficial nature of the process explains why patients report only mild discomfort rather than the severe, boring pain seen in scleritis.

Most cases are idiopathic, but roughly one-third of patients have an underlying systemic inflammatory condition. The proposed mechanism involves a localized immune-mediated vasculitis of the episcleral vessels, triggered either by circulating immune complexes or local immune dysregulation.

A key clinical correlate of this superficial pathology is the phenylephrine blanching test. Topical phenylephrine 2.5% constricts the superficial episcleral vessels, causing the redness to fade. In scleritis, the deeper scleral plexus is inflamed and does not blanch, leaving a violaceous (blue-red) hue visible after phenylephrine application.

02Classification and Clinical Manifestation

Classification of Episcleritis

Scleritis vs. Episcleritis Comparison

This is the highest-yield table for exam purposes. The test-writer's goal is to see whether you can distinguish these two conditions, because their initial appearance overlaps.

The quality of pain, the phenylephrine response, and the color of redness are the three pillars that separate these diagnoses.

03Diagnostic Workup

Episcleritis is fundamentally a clinical diagnosis. In a straightforward first-episode presentation with unilateral sectoral redness, mild discomfort, normal vision, and a positive phenylephrine blanching test, no further workup is needed.

The phenylephrine test deserves emphasis because it is the most testable diagnostic maneuver. You instill one drop of phenylephrine 2.5% and reassess after 10-15 minutes. If the redness fades, the inflamed vessels are superficial (episcleral), confirming episcleritis. If the redness persists with a deep violaceous color showing through, the inflammation is scleral, and the diagnosis shifts to scleritis.

Slit-lamp examination should be performed to rule out concurrent anterior uveitis (which would suggest scleritis or another inflammatory process). In episcleritis, the anterior chamber is quiet with no cells or flare.

A systemic workup is not routine for a single uncomplicated episode. However, it becomes indicated when the patient presents with recurrent episodes, bilateral involvement, or the nodular subtype, as these patterns carry a higher likelihood of an underlying autoimmune condition. In that scenario, order ANA, rheumatoid factor, ESR/CRP, and consider ANCA if granulomatosis with polyangiitis is suspected.

04Management and Treatment

The cornerstone of management is reassurance and supportive care. Most episodes of episcleritis resolve spontaneously within 7-14 days without treatment. This self-limiting nature is itself a testable point: on the exam, the correct answer for a classic uncomplicated episcleritis vignette is often conservative management rather than aggressive pharmacotherapy.

Artificial tears provide symptomatic relief by reducing the foreign body sensation and mild irritation. Cold compresses can also help.

When discomfort interferes with daily activities, oral NSAIDs are the first-line pharmacologic therapy. Ibuprofen (400 mg three times daily) or naproxen (250-500 mg twice daily) for 1-2 weeks is standard. Note that the exam may test the preference for oral over topical NSAIDs, as oral agents address the episcleral inflammation more effectively than topical formulations for this condition.

Topical corticosteroids (prednisolone acetate 1%) are reserved for cases that fail to respond to oral NSAIDs. They should only be prescribed under ophthalmology supervision due to the risks of steroid-induced glaucoma and cataract formation. The exam commonly tests the principle that topical steroids are not first-line for episcleritis.

If a patient experiences three or more recurrences, a systemic autoimmune workup and rheumatology referral are warranted to investigate for conditions such as rheumatoid arthritis, lupus, or inflammatory bowel disease.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss episcleritis questions is by overdiagnosing scleritis. When a vignette describes a red eye, many students default to the more dangerous-sounding diagnosis without checking for the discriminating features. The exam rewards you for recognizing that episcleritis is benign, self-limiting, and painless (or nearly so). If the patient has no severe pain, no vision change, and no globe tenderness, the answer is almost certainly episcleritis, not scleritis.

A second trap is the management question. Students who recognize episcleritis correctly may still choose topical corticosteroids as first-line therapy. The tested principle is that oral NSAIDs precede topical steroids, and many cases need nothing more than artificial tears and reassurance.

The phenylephrine blanching test is the single most testable clinical maneuver in this topic. If the vignette mentions that redness fades after instilling phenylephrine drops, the answer is episcleritis. If it does not blanch, think scleritis. This test appears frequently and should be committed to memory as an automatic trigger.

Finally, remember the association threshold: a single uncomplicated episode requires no systemic workup. Recurrent, bilateral, or nodular presentations warrant investigation for autoimmune conditions. The exam tests whether you know when to escalate the evaluation versus when to manage conservatively.